Indinol 300 mg + Epigallate 0.5 g N120x2 capsules

Indinol + Epigallate (No. 120 caps + No. 120 caps)

A country

Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Compound

Composition for 1 capsule of Epigalate. Active ingredients: epigallocatechin-3-gallate, at least 45 mg and mineral premix. Composition for 1 capsule of Indinol. Active ingredients: indole-3-carbinol, at least 90 mg.

pharmachologic effect

The active substances of Epigallate have multiple etiopathogenetic effects in relation to hyperplastic processes of the reproductive system. Suppresses pathological growth and cell division in organs and tissues of the female reproductive system caused by non-hormonal stimuli. Reduces the invasive activity of endometrial cells, and also causes selective death (apoptosis) of cells with increased proliferative activity. Epigallate has a pronounced antiangiogenic effect (suppresses the pathological growth of new vessels) and thus prevents the growth of tumors. It is an effective anti-inflammatory agent, suppressing the activity of type 2 cyclooxygenase, prostaglandides and the synthesis of pro-inflammatory cytokines, and in addition, enhances the effect of antibiotics (tetracyclines, beta-lactams) and increases the sensitivity of resistant microorganisms to the action of antibacterial agents. It has a pronounced antioxidant effect, neutralizing the formation of free radicals. Indinol is a universal corrector of pathological hyperplastic processes in the organs and tissues of the female reproductive system (breast, endometrium, myometrium, cervix, ovaries). Normalizes the balance of estrogen in the body and suppresses their negative stimulating effect, and also blocks other (hormone-independent) mechanisms that activate pathological cellular growth in the tissues of the mammary gland and uterus. It has the ability to cause selective death of transformed cells with abnormally high proliferative activity.

Indications for use

Recommended as a dietary supplement to food, an additional source of flavonoids and a source of indinol-3 carbinol.

Mode of application

As part of combination therapy (endometrial hyperplasia without atypia, endometriosis, adenomyosis, uterine fibroids), it is recommended to take 2 capsules (Epigalate) + 2 capsules (Indinol) orally with meals for 6 months. For genital diseases associated with the human papillomavirus, Indinol is recommended to be taken orally 2 capsules 2 times a day in combination with immunomodulator drugs used as standard treatment for these diseases. In this case, both sexual partners must undergo treatment.

Interaction

No data.

Side effect

It is well tolerated, without causing side effects in therapeutic doses.

Contraindications

Individual intolerance to components; Not recommended for people taking medications that reduce gastric acidity, as well as for pregnant and lactating women.

Overdose

No data.

special instructions

It is recommended to consult a doctor before use. Not a medicine.

Publications in the media

I.S. SIDOROVA, head of the department, corresponding member of the Russian Academy of Medical Sciences A.L. UNANYAN, Associate Professor of the Department, Doctor of Medical Sciences N.V. KARASEVA, postgraduate student of the department of the Department of Obstetrics and Gynecology, FPPOV MMA named after. I. M. Sechenova

Uterine fibroids and adenomyosis are among the most common gynecological diseases after inflammatory processes. During preventive examinations, uterine fibroids are first detected in 1-5% of subjects, among gynecological patients - up to 30-35%. Endometriosis occurs in women of any age, regardless of social status and ethnicity. According to some scientists, the incidence of genital endometriosis ranges from 12 to 50%. The frequency of co-occurrence of uterine fibroids and adenomyosis is quite high and ranges from 35 to 80%.

An urgent task of gynecology is organ-preserving treatment of patients with uterine fibroids and adenomyosis. The current therapy with hormonal drugs for uterine fibroids and adenomyosis has a number of significant drawbacks. After cessation of hormonal treatment, most patients experience a relapse of clinical symptoms. The severity of side effects and the large number of contraindications to hormonal therapy also deserve attention.

As a result of numerous studies of hormonal status and hormone receptors in uterine fibroids, ambiguous results have been obtained, indicating the heterogeneity of fibroids. Currently, the role of other, previously unknown factors in the genesis of the combination of uterine fibroids and adenomyosis has been proven, namely: disruption of the processes of apoptosis, proliferation, neoangiogenesis, and stromal formation in the development of these diseases. The literature describes substances with antiproliferative, antiangiogenic and proapoptotic effects, in particular indole-3-carbinol and epigallocatechin-3-gallate. Indole-3-carbinol has powerful antitumor activity, pathogenetically affecting the main links in the development of hyperplastic processes in the body. Epigallocatequin-3-gallate is one of the representatives of catechins, has the strongest antioxidant activity, comparable to setocofferol, as well as anti-inflammatory, antiproliferative and antiangiogenic effects.

The effects of these drugs have been studied in various pathological models in studies by scientists from different countries. However, there is not yet enough scientific research to study the effects of these drugs in the combination of uterine fibroids and adenomyosis. In this regard, a clinical study was conducted on the effectiveness of drugs containing indole-3-carbinol and epigallocatechin-3-gallate in patients with a combination of uterine fibroids and adenomyosis.

The study included 92 patients aged 35–49 years (mean age 42±7 years), who had no indications for surgical treatment and were prescribed hormonal therapy. The patients were divided into 2 groups. The first included 47 people who were prescribed gonadotropin-releasing hormone (GnRH) agonists: buserelin depot 3.75 mg/month intramuscularly or triptorelin 3.75 mg/month intramuscularly for 6 months. The second group included 45 people who received therapy with GnRH agonists and drugs containing indole-3-carbinol 400 mg/day (the drug Indinol 2 capsules 2 times a day with meals) and epigallocatechin-3-gallate 200 mg/day days (Epigallate, 2 capsules 2 times a day with meals) for 6 months. The patients were concerned about general weakness and increased fatigue (19.6%). The predominant symptoms were heavy and prolonged menstruation (72.8%), painful menstruation (41.3%), perimenstrual bleeding (38%), pain in the lower abdomen (13%), acyclic bleeding (9.8%), dyspareunia ( 16.3%), dysuric symptoms (12%). Of the 61 (66.3%) patients of reproductive age with a combination of uterine fibroids and adenomyosis, there was primary (2.2%) or secondary (3.3%) infertility. The duration of combined uterine disease ranged from several months to 14 years (on average 7.6±1.5 years). During therapy with GnRH agonists, a noticeable decrease in uterine volume was observed in all patients of the first group. The maximum reduction of the uterus was 42-45% of the initial volume by the end of the 6-month course of treatment. However, after the end of the course of treatment, growth of the uterus was noted, and 6 months after the end of treatment, the volume of the uterus reached its previous size. The same trend was observed when studying the volume of the dominant node and assessing the thickness of the uterine wall with adenomyosis.

When using GnRH agonists, side effects were observed: “hot flashes” to the head, neck, and body were noted in most patients and did not depend on the drug used, occurring in 75-80% of patients. Patients also noted headaches (24%), irritability (18%), sweating (17%), sleep disturbances (11%), dry mucous membranes and discomfort during sexual activity (10%), decreased libido (10%), swelling legs, face (5%). There were no complications or severe side effects that could lead to discontinuation of the drug. We observed a slightly different clinical picture in women of the second group. In this group of patients, a significant gradual decrease in uterine volume was also observed. In the case of simple fibroids, after 3 months the volume of the uterus decreased by 32%, after 6 months - by 57%. In the case of proliferating fibroids, after 3 months a decrease in the volume of the uterus was diagnosed by 43.5%, after 6 months - by 59.5%, which coincided with the dynamics of the decrease in the volume of the uterus in patients of the first group. But after discontinuation of the drugs, the growth of the uterus was not as significant as in patients of the first group. The same trend was noted when assessing the dynamics of the dominant fibroid node and the thickness of the uterine wall with adenomyosis. It should be noted that side effects in the second group of patients were associated with the use of GnRH agonists. None of the patients reported any side effects associated with taking Indinol or Epigallate.

conclusions

In connection with the study, we can conclude that the use of GnRH agonists as an independent method in patients with preserved menstrual function is not effective enough. And the addition to treatment of drugs containing indole-3-carbinol (Indinol) and epigallocatechin-3-gallate (Epigallate), which affect the molecular mechanisms of uterine fibroids and adenomyosis - apoptosis, proliferation, neoangiogenesis, has shown good clinical efficacy in the treatment of a combination of uterine fibroids and adenomysis.

Thus, new ways of pharmacological correction of uterine fibroids and adenomyosis have been identified. The use of the drugs Indinol and Epigallate, which influence the main pathogenetic mechanisms of the development of fibroids and adenomyosis, opens a new direction in the treatment of these diseases - targeted therapy. Such therapy should become a priority for practitioners in the treatment of uterine fibroids and adenomyosis.

How to replace Epilagat on iHerb?

A safe and effective analogue of Epigallate is green tea extract EGCg from Now Foods. You can purchase it in the iHerb online store. The dietary supplement contains epigallocatechin gallate, which minimizes the risk of developing breast cancer, as well as other diseases of the female genital area.

Green Tea Extract EGCg on iHerb

Introduction

In the structure of gynecological pathology, adenomyosis ranks third in frequency after inflammatory diseases and uterine fibroids.
Based on indirect data, it is calculated that adenomyosis occurs in 20–25% of women of reproductive age [1]. The high clinical significance of adenomyosis is due to its influence on the quality of life of the most active part of the female population. Heavy bleeding occurs in 50–98% of patients with adenomyosis, which leads to the development of anemia in 30–50% of patients. Infertility occurs in 9–40% of patients with adenomyosis, and in the structure of the causes of female infertility, adenomyosis ranks second after tubal factor, accounting for 20% [2]. The pain syndrome, initially clearly associated with the menstrual cycle, subsequently manifests itself at any time, which also significantly affects the quality of life of women. Dyspareunia and chronic pelvic pain syndrome lead to disruption of the family life of patients. An important factor determining the clinical significance of adenomyosis is the low effectiveness of conservative therapy. At the same time, the prescription of gonadotropin-releasing hormone agonists, the most effective drugs in the treatment of adenomyosis, causes side effects that often reduce the quality of life even more than the disease itself. None of the numerous analgesic agents, including the most modern drugs, is without drawbacks, so long-term pain management remains a clinical challenge. The desired analgesic effect can formally be considered symptomatic, but the suppression of any sign of the disease is always associated with the elimination of its specific pathogenetic link. In this aspect, the drugs Indinol (indole-3-carbinol) and Epigallate (epigallocatechin-3gallate) (MiraxPharma, Russian Federation) deserve attention, which have the ability to pharmacologically correct molecular biological processes. Drugs have an effect at the molecular level. Indinol inhibits pathological cell proliferation and induces apoptosis in tumor cells. The drug Epigallate blocks neoangiogenesis, inhibits invasive processes in diseases of tumor and non-tumor nature, exhibits a selective antiproliferative effect against actively dividing cells and regulates the activity of the cell cycle, thus enhancing the effect of Indinol [3, 6]

The purpose of the study was to evaluate the effectiveness of therapy with Indinol and Epigallate in women suffering from pelvic pain due to adenomyosis.

Material and methods

In 50 patients aged 25 to 45 years, using a complex of clinical research methods, hysteroscopy, and ultrasound examination of the pelvic organs, internal endometriosis of the uterine body of varying degrees of spread was detected. The menstrual cycle from menarche was not disrupted in 40 (80%) women. Every fifth (10%) woman suffered from infertility. The main complaint that led to seeking medical help was constant aching pain in the lower abdomen in 46 women, pain during menstruation - in 50, prolonged painful and heavy menstruation - in 48, painful sexual intercourse - in 35, deterioration in general condition was observed in 50 women , sleep disorders – in 37. To assess the quality of life, we used the Russian version of the SF-36 (Health Status Survey) questionnaire [5], the questions in which are grouped into eight scales: physical functioning, role activity, bodily pain, general health, vitality, social functioning, emotional state and physical health, and the results are presented in the form of scores. A higher score indicates a higher level of quality of life.

During a bimanual examination of the uterus, an increase in its size up to 6–7 weeks of pregnancy was observed in 34 (68%) women, heterogeneous consistency - in 16 (32%), pain on palpation and attempted displacement - in 41 (82%). 15 (30%) women had relative indications for surgery, but we decided to make a final attempt at more gentle treatment, taking into account its potential pathogenetic validity. All patients took Indinol daily, 2 capsules 2 times a day in combination with Epigallate - 2 capsules 2 times a day for 9 months. At the same time, anti-inflammatory, absorbable therapy was carried out for 2 weeks in the gynecological department, which included immunocorrectors, antioxidants, vitamins, desensitizing agents and physiotherapy.

Results and discussion

As a result of the treatment, a decrease in the manifestations of clinical symptoms was noted. Constant aching pain in the lower abdomen persisted in 12 women, pain during menstruation - in 5, long and heavy menstruation - in 4, painful sexual intercourse - in 6. Improvement in general condition was noted by 45 women, restoration of sleep was observed in 47 patients (see figure ). The results of assessing the quality of life before and after treatment are presented in the table. As follows from these data, quality of life indicators increased and, accordingly, the severity of mood changes, depression, and anxiety decreased in 37 (74%) patients.

.Assessment of quality of life according to the scales of the SF-36 questionnaire in patients with adenomyosis before and after treatment (scores).

After treatment, a control ultrasound of the pelvic organs with color Doppler mapping in 30 (60%) women showed a decrease in foci of adenomyosis, vascularization in areas of adenomyosis was less pronounced, single vessels with moderately resistant blood flow were identified (IR = 0.5–0.7) . When taking medications, only four patients reported side effects in the form of epigastric pain associated with taking medications; moderate nausea after taking them was observed in two patients.

Conclusion

Thus, the study indicates that the use of antiproliferative drugs Indinol and Epigallate can reduce heterotopic endometrial inclusions in the myometrium, improve the state of myometrial architecture and thereby alleviate the clinical manifestations of the disease, accompanied by debilitating pelvic pain. Heterotopias in adenomyosis are derivatives of the basal, and not the functional layer of the endometrium, and therefore previous hormonal therapy in 12 (24%) patients with adenomyosis was less effective, in contrast to the treatment of women with foci of external genital endometriosis. The use of Indinol and Epigallate, which inhibit pathological proliferation, for the treatment of women with pelvic pain syndrome due to internal endometriosis of the uterine body is an effective and pathogenetically substantiated method of treatment. Our data indicate that Indinol and Epigallate prevent the progression of a chronic pathological process in the pelvis, improve the quality of life of patients and may be an alternative to non-narcotic analgesics, antispasmodics, hormonal drugs, and in certain clinical situations - surgical treatment.

Information about the authors: Neimark Alexander Izrailevich – Doctor of Medical Sciences, Professor, Head of the Department of Urology and Nephrology of the Altai State Medical University, Chief urologist of the Altai Territory. Tel.; Shelkovnikova Natalya Vasilievna – Candidate of Medical Sciences, obstetrician-gynecologist, urologist at the gynecology department of JSC Russian Railways National Healthcare Institution OKB st. Barnaul. Tel.

Who is prescribed Epigallate?

Most often, the drug Epigallate is prescribed for simultaneous use with indinol (which also has an inexpensive analogue, Indole-3 Carbinol) for the treatment of female pathologies - uterine fibroids, mastopathy, etc. This expensive medication is recommended to be taken for at least six months.

The main active ingredient of Epigallate is epigallocatechin gallate. It is a type of green tea catechins. Theoretically, the required amount of this substance can be obtained by drinking several cups of fresh infusion of tea leaves. But the fact is that catechins from the drink are not fully absorbed. That is why patients are prescribed medications containing the substance in the required dosage.

Instructions for use EGCg

The manufacturer recommends taking 1 capsule of EGCg daily with meals. One package contains 90 or 180 capsules. This is enough for the entire course of treatment, which usually lasts three months.

Important! The period of therapy can be increased only in consultation with the doctor. The specialist will assess the patient’s condition, the presence of chronic diseases and other significant factors. Based on all this data, a decision will be made on the possibility of undergoing a second course of treatment.

Thanks to the soluble capsule shell, catechins pass through the digestive tract, end up in the intestines and from there begin to be actively absorbed into the circulatory system. Once in the body, these substances stop pathological growth and cell division in the area of ​​the reproductive organs of women, strengthen the immune system, and eliminate chronic fatigue.

Epigallate and analogues on iHerb

Let's compare epigallate and analogues on iHerb, for example, EGCg, green tea extract from Now Foods. Epigallate is usually prescribed for joint use with indinol in the treatment of female diseases - mastopathy, uterine fibroids and some others. Treatment is expensive. Usually a course of at least 6 months is prescribed.

Indole-3-carbinol and epigallocatechin gallate are active phytochemicals that are present in certain plants and are the main active ingredients in these preparations. We have already discussed in detail the presence of indole-3-carbinol in food products.

Epigallocatechin gallate is a type of green tea catechin that can in principle be obtained by drinking a certain number of cups of green tea, but the method is very unreliable and questionable. Epigallate is a dietary supplement containing 45 mg of pure epigallocatechin gallate. The price is steep. In my opinion, there is no point in overpaying for a supplement if you can buy an identical one much cheaper.

Epigallate and analogues: comparison table

As you can see from the table, a daily dose of treatment with EGCg, green tea extract from Now Foods will cost ten times less. A six-month course of treatment with this drug costs 1,041 rubles.

The dosage of one capsule of epigallate is much lower (45 mg versus 200 mg), it is taken two capsules twice a day. For a course of treatment you need to buy 6 packages of 120 capsules, which is already 11,244 rubles. The difference is 10 thousand rubles!

Side effects and contraindications

The EGCg dietary supplement is well tolerated and very rarely causes allergic reactions. In its production process, no components of animal origin, milk, soy, seafood, gluten, or nuts are used. EGCg does not contain artificial flavors, colors, or sugar substitutes.

Before you start taking EGCg, you need to consider certain restrictions:

• during pregnancy and lactation, use of the supplement is possible only under the supervision of a specialist;
• if you have chronic diseases, including liver failure, you should also consult your doctor;
• The dietary supplement is intended only for adult patients.

EGCg is an inexpensive but effective analogue of Epigallate. It improves the general condition of a woman, eliminates pathological processes in the reproductive system. You can purchase EGCg from the trusted manufacturer of dietary supplements Now Food in the American online store IHerb.